# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T18:27:29.309767
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 16542 in / 5990 out
**Response SHA256:** ff31986fd3cfd818

---

Thank you for the opportunity to review this paper. This is an interesting and policy‑relevant project that uses modern staggered-DiD methods to estimate the population-level effects of Energy Efficiency Resource Standards (EERS). The paper is promising: it asks a clear question, uses high-quality data, and applies recent econometric tools (Callaway & Sant’Anna, Sun–Abraham, SDID). However, several substantive methodological and presentation issues must be addressed before this is publishable in a top general-interest journal.

Below I provide a comprehensive review organized by the requested sections: format, statistical methodology (critical), identification, literature, writing quality, constructive suggestions for strengthening the paper, overall assessment, and a recommended decision.

1. FORMAT CHECK

- Length: The LaTeX source contains a full paper with introduction, data, methods, results, appendix and references. Judging from the content, figures and tables, the rendered PDF would likely be in the 25–40 page range (main text + appendix). I estimate ~30 pages excluding references/appendix. That meets the stated minimum (≥25 pages). Please confirm the final page count in the submitted PDF.

- References: The bibliography cites most of the essential recent methodological papers for staggered DiD (Callaway & Sant’Anna 2021; Goodman‑Bacon 2021; Sun & Abraham 2021; Arkhangelsky et al. 2021; Rambachan & Roth 2023; de Chaisemartin & D’Haultfoeuille 2020; Sant’Anna & Zhao 2020). It also cites relevant energy econ and evaluation literature. Overall coverage is good, but see Section 4 for additional citations that should be added.

- Prose: Major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Robustness, Discussion, Conclusion) are written in paragraph form, not bullets. Good.

- Section depth: Most major sections (Introduction, Institutional Background, Conceptual Framework, Data, Empirical Strategy, Results, Robustness, Discussion) contain multiple substantive paragraphs. A few subsections (e.g., some robustness descriptions) are concise but acceptable. Each major section has 3+ substantive paragraphs in the main text.

- Figures: The LaTeX source references several figures (raw trends, rollout, event study, robustness forest, group ATT). The code uses includegraphics with file names. I could not visually inspect the rendered figures from the LaTeX source you provided; make sure all figure files are present in the submission and that each figure includes readable axes, labels, and units, and that legends are clear. In particular ensure color palettes are accessible in greyscale and color-blind friendly.

- Tables: Tables in the source include numeric results (e.g., Table 1 summary stats, Table of main results). I see no placeholder numbers. Make sure all tables have notes explaining units, sources, and how missingness is handled.

Format issues to fix before resubmission:
- Make sure figures are included and legible in the submission PDF. Include units on all axes and state-sample‑size annotations where relevant (e.g., event-study figure should indicate number of cohorts contributing at each event time).
- In tables, explicitly report N (state‑years) for each regression column (Table 3 already reports Observations = 1,479, but include N by treatment/cohort if you later present cohort-specific or SDID balanced-panel regressions).
- Provide a clear list of files in the project repository that were used to build the PDF, and include script(s) necessary to reproduce the figures/tables (helpful for reviewers/editors).

2. STATISTICAL METHODOLOGY (CRITICAL)

A paper cannot pass review without defensible statistical inference. Below I summarize what the paper does well and what is missing/problematic. Some items are fatal unless fixed; others are fixable but important.

Positive points:
- The author uses heterogeneity-robust estimators appropriate for staggered adoption: Callaway & Sant’Anna (doubly‑robust CS‑DiD), Sun & Abraham, and synthetic DiD (Arkhangelsky et al.). This addresses a major methodological pitfall with TWFE in staggered settings.
- The paper reports standard errors for coefficients (Table 3 includes SEs in parentheses) and 95% CIs in brackets for the main table.
- The paper reports sample sizes (Observations = 1,479; Treated States = 28; Control States = 23) in Table 3.
- The author conducts several robustness checks: alternative control groups (never-treated and not‑yet‑treated), alternative estimators (TWFE, Sun–Abraham, SDID), exclusion of pandemic years, controls for concurrent policies, and an Honest DiD sensitivity analysis (Rambachan & Roth).

Critical problems / required fixes (must be addressed):

a) Standard errors and inference for the preferred estimator (CS‑DiD):
- The preferred estimate (Column 1) is CS‑DiD and is reported with a clustered SE. However, the paper relies on analytical clustered SEs for the CS estimator but applies a wild cluster bootstrap only to TWFE (Column 2). With 51 clusters, cluster-robust asymptotic inference can be unreliable. The paper acknowledges this (Section 7.2) but does not present a bootstrap or other small-cluster-robust inference for the main CS‑DiD results.
Action required: Report inference for the main CS‑DiD ATT using a robust method appropriate for a small number of clusters: options include the wild cluster bootstrap (Mammen or Rademacher weights) applied to the CS‑DiD point estimate (if implementation exists), the permutation/randomization inference approach (permutation over treatment assignment consistent with rollout), or the cluster-robust t‑stat with adjustments (e.g., satisfactory CR2 standard errors if supported). If current software does not support wild bootstrap for the CS‑DiD implementation you use, provide inference via alternative distribution‑free approaches (e.g., randomization-based placebo distribution by reassigning treatment years among states while preserving cohort sizes) and report p‑values and CIs from those procedures. At minimum, present wild-cluster bootstrap p‑values/CIs for the CS‑DiD main ATT (not only TWFE). If not possible, explain and justify the approach thoroughly.

b) Multiple inference reporting:
- The paper states p-values like p<0.01. Given the inference fragility, present both analytical cluster-robust SEs and bootstrap/pseudo‑permutation p‑values and 95% CIs for each main estimate. For event-study coefficients, show pointwise and joint (e.g., simultaneous) confidence bands, and report how many pre-period coefficients are statistically different from zero (and the p-values). Event-study pre-tests are informative but can be misleading (Roth 2022); show the distribution of placebo pre-coefficients under randomization/permutation inference.

c) Honest DiD is used and demonstrates fragility — good — but present a clearer explanation of what M corresponds to in substantive terms (e.g., how many percentage points of pre-trend per year) and show how results evolve across a sensible grid of M. Provide both visual and tabular displays.

d) Staggered DiD specifics:
- The CS approach requires that never-treated states are a valid control group for each cohort. The paper uses never-treated as the main control group which is defensible, but you must demonstrate that no cohort is being compared primarily to cohorts with very different pre-trends or that the composition of controls changes dramatically across event times. Present and discuss cohort‑level diagnostic plots: (i) number of contributing treated cohorts to each event time; (ii) number of never-treated states in each comparison; (iii) the cohort‑specific pre‑trends and ATTs (Callaway & Sant’Anna allow group‑time ATTs — show them). If any cohort is driving long-run effects (e.g., early adopters), explicitly show cohort-specific results.

e) TWFE (staggered) problems:
- You correctly note that TWFE is biased with heterogeneous effects. That is fine. Continue to include TWFE for comparison but do not rely on it.

f) RDD rules are not applicable; you do not use RDD. (No action).

g) Placebo/permutation tests:
- Provide placebo tests where treatment years are randomly assigned to states (preserving cohort sizes and temporal structure) and compute the distribution of ATT estimates under the null. Compare your actual ATT to this distribution. This is especially important given the small number of clusters and the sensitivity shown by Honest DiD.

h) Pre‑trend diagnostics beyond visual inspection:
- Implement and report formal pre-trend tests following Sant’Anna & Zhao (2020) or Roth (2022), and perform placebo event‑studies estimated with not‑yet-treated controls as a falsification exercise. The current event study shows flat pre-trends visually but a formal test improves credibility.

i) Inference for heterogeneous and long‑run effects:
- Long-run event times (10–15 years) are identified by early cohorts only. Provide standard errors that account for the small number of early‑cohort contributors (possibly use jackknife or leave‑one‑out for early cohorts) and be explicit that long‑run estimates reflect experiences of early adopters.

j) Treatment intensity and measurement:
- The treatment is coded as a binary first‑adoption indicator. Many EERS differ in stringency (targets vary 0.4%–2% per year). The paper asserts the magnitude scales with target size, but no dose‑response regressions are presented. Consider re-specifying treatment as continuous (e.g., first-year mandated savings target θs) or adding interactions with per‑capita program spending or savings targets where available (Form 861 DSM spending). If you cannot obtain good intensity measures, make that limitation explicit in the main text and not only in Discussion.

Summary (statistical methodology): The statistical approach is appropriate in spirit, but the inference is currently incomplete for your preferred estimator. The main ATT must be accompanied by robust small‑cluster inference (wild bootstrap or permutation) and extensive cohort‑level diagnostics. The fragility shown by Honest DiD is important; you must follow up with permutation/placebo procedures, cohort‑level ATTs, and show that results are not driven by a small set of early adopters or by correlation with other contemporaneous policies.

3. IDENTIFICATION STRATEGY

Is identification credible? The paper uses CS‑DiD with never‑treated controls and presents event studies and sensitivity checks. The main identification threats are discussed (concurrent policies, anticipation, compositional change). Below I list strengths and weaknesses and recommended additional diagnostics.

Strengths:
- Use of modern estimators tailored for staggered adoption.
- Event-study showing visually flat pre-trends for the residential outcome.
- Controls for concurrent RPS/decoupling and weather (HDD/CDD).
- Honest DiD sensitivity analysis is a good and required robustness check.

Remaining concerns / suggested fixes:

a) Parallel trends assumption: you state event-study pre-treatment coefficients are centered on zero for a decade. But: (i) you must provide formal pre‑trend tests (see Sant’Anna & Zhao 2020; Roth 2022), and (ii) demonstrate that the pre-trend result holds for each major cohort or region. If some cohorts show pre-trend departures, the aggregated event-study can mask cohort-specific violations. Present cohort-specific event studies or at least cohort-level pre-trend tests.

b) Concurrent policy confounding: EERS adoptions often coincide with Renewable Portfolio Standards (RPS), decoupling, building codes, or economic shocks. You control for RPS and decoupling, but (i) data on building code upgrades, appliance standards, or state economic shocks (manufacturing declines) should be added if available, and (ii) triple-difference or stacked DiD designs could help isolate EERS from co‑adopted policies: for example, compare treated states to never-treated states and to states that adopted RPS but not EERS (if any), or use a difference-in-difference-in-differences that exploits sectoral exposure (residential vs industrial) and EERS targeting of sectors.

c) Industrial outcome oddity: The large negative industrial result (–19%) is a red flag. It suggests either (i) a compositional effect (deindustrialization) that is correlated with EERS adoption, or (ii) misattribution of effects from other concurrent policies or economic changes. You attempt to explain this in Discussion, but more empirical work is needed:
- Explore whether industrial declines pre-date EERS adoption in affected states (cohort-level pre-trends for industrial consumption).
- Control for state-level manufacturing employment, value added, or industry composition to see whether the residential ATT is sensitive to these controls.
- Conduct a triple-difference: residential vs industrial changes within each state around EERS adoption; if residential declines AND industrial declines move together because of broader shocks, the triple‑difference may vanish.
- Alternatively, omit states where industrial contraction coincides with EERS adoption as a sensitivity check; report how the residential ATT changes.

d) Anticipation and early implementation: You address this via event study, but also consider coding treatment as starting at policy passage vs first year of binding mandate and testing sensitivity to different treatment dates (passage vs effective date vs first full program year). If utilities implemented programs before the statute's effective date, the event‑study coding matters.

e) Time‑varying confounders and region-specific shocks: You include a census-division-by-year FE in a specification (mentioned in the Introduction/Robustness), which is good. Also consider state-specific linear trends as a robustness check. The cost: state trends can soak up part of the treatment effect; but presenting estimates with and without state trends helps bound the effect and demonstrates robustness to smoothly varying unobservables.

f) External validity / generalization: You note never-treated states are concentrated in the Southeast and Mountain West. Explicitly present a table or figure mapping treated vs never-treated states to show geographic clustering. Consider re-estimating the ATT using a matched control set of states (e.g., via propensity-score matching on pre-treatment trends and covariates) to show results are not driven by regional differences.

4. LITERATURE (Provide missing references)

The paper cites the most important recent methodology papers and the key energy-economics literature. A few relevant methodological and applied references should be added to strengthen the positioning and to show awareness of recent work on event studies, inference with a small number of clusters, and placebo/randomization inference. I recommend including the following (BibTeX entries provided).

a) Placebo/randomization inference and event-study diagnostics:
- Freyaldenhoven, Gardner & Prager (2019) — a widely cited paper about event-study inference in staggered adoption settings. If your event-study inference relies primarily on visual inspection, cite and use this work to motivate permutation/placebo tests.

BibTeX:
```bibtex
@article{Freyaldenhoven2019,
  author = {Freyaldenhoven, Simon and Gardner, Jonah and Prager, Edward},
  title = {How to (and How Not to) Test for Parallel Pre-Trends in Event Study Designs},
  journal = {Working Paper},
  year = {2019}
}
```
(Note: if you prefer a more stable citation, substitute the exact publication if it exists; the authors have circulated Working Papers on this topic.)

b) Permutation / randomization inference for DiD with few clusters:
- Conley and Taber (2011) is cited; also include Moulton or others? You already cite Conley & Taber (2011) and Cameron/Gelbach/Miller (2008) and MacKinnon & Webb (2018). That coverage is adequate, but be sure to (i) use their recommended inference approaches and (ii) cite where you apply them.

c) Design-based/event-study literature:
- Borusyak & Jaravel (2022) — they propose robust event-study methods (I see a 2024 citation in your references to Borusyak et al.; ensure you cite the correct paper you used and include full BibTeX).

d) Dose-response / continuous treatment in staggered designs:
- If you later implement dose-response (treatment intensity), consider citing Callaway, Li, and Ogburn or relevant extensions. For a basic reference about continuous DiD, see Sant’Anna & Zhao 2020 (already cited).

If you want me to prepare additional specific BibTeX entries for other papers you'll use (e.g., Freyaldenhoven et al. final publication details or Borusyak et al.), please provide the precise publication information and I will include it.

5. WRITING QUALITY (CRITICAL)

Overall the prose is clear, readable, and well organized. The paper tells a compelling policy story. That said, several improvements will raise clarity and help readers outside the narrow methods literature.

a) Prose vs bullets: Good — full paragraphs everywhere.

b) Narrative flow:
- The Introduction hooks the reader and summarizes contributions clearly. The Motivation → Method → Findings → Implications logical arc is present.
- However, the Discussion sometimes doubles as an extended results interpretation; I suggest moving some of the methodological caveats (Honest DiD fragility) earlier into the Results/Robustness section so readers can evaluate claims with that context in mind before the welfare calculation.

c) Sentence quality:
- Generally crisp. A few long paragraphs (e.g., the longer parts of the Introduction) could be split for readability.
- Avoid overconfident statements when sensitivity analysis shows fragility (e.g., reduce phrasing like “I estimate that EERS mandates lower residential electricity consumption by 4.2 percent (p<0.01)” to “The preferred estimate is –4.2% (clustered SE = 0.0096); the result is robust across estimators, but sensitivity analyses suggest modest violations of parallel trends could render the effect statistically insignificant”).

d) Accessibility:
- Terms like “free‑rider” and “rebound effect” are well explained.
- Provide an intuitive description of the Callaway & Sant’Anna estimator in one short paragraph (why it differs from TWFE, what it requires).
- For the Honest DiD analysis: explain in plain language what M means and how it maps to a plausible economic differential trend (e.g., “M = 0.01 corresponds to a drift of 0.01 log points per year in treated states relative to controls” or similar).

e) Tables:
- Table notes are helpful. For main regression tables, add a column that reports the p‑value from the wild-cluster bootstrap or permutation test next to the analytical SE/p-value.
- For the event study figure, add the number of contributing cohorts at each event-time on the panel (small tick/bar below the x-axis).

6. CONSTRUCTIVE SUGGESTIONS (to make the paper more impactful)

The paper is close to being a strong contribution. Below are concrete analyses and presentation changes that would substantially strengthen credibility and contribution.

A. Strengthen inference for the main CS‑DiD ATT:
- Implement wild cluster bootstrap or permutation-based inference tailored to the CS‑DiD estimator. If not available in your software, implement a randomization inference that permutes treatment years among states preserving cohort sizes and re-estimates the CS‑DiD ATT many times to produce a null distribution.
- Report both analytical clustered SEs and bootstrap/permutation p-values and CIs.

B. Cohort-level diagnostics and decomposition:
- Present cohort‑level ATTs and pre‑trend plots for each major adoption cohort (e.g., 1998–2004 early adopters, 2005–2008, 2016–2020). Show which cohorts drive long‑run effects.
- Provide Goodman‑Bacon decomposition weights (you note this in Appendix) but present a table/figure that makes clear how much each type of comparison contributes to the TWFE estimate and why TWFE is attenuated.

C. Address the industrial-sector anomaly:
- Explore whether industrial declines pre-date EERS or whether they are contemporaneous. Control for manufacturing employment, state GDP, or value added by industry if available, and show the residential ATT sensitivity.
- Perform a triple-difference using sectoral exposure: residential change minus industrial change in treated vs controls. If EERS truly targets residential and commercial sectors, the triple-difference should preserve effect on residential but eliminate economy-wide shocks.

D. Dose-response and intensity analysis:
- If possible, incorporate state‑level EERS target stringency or annual DSM spending per capita (from EIA Form 861 or ACEEE program spending tables). Estimate continuous treatment effects (e.g., per 0.5% change in mandated annual savings or per \$ of DSM spending per customer).
- If data quality for spending is poor, at least classify states into high/medium/low‑ambition EERS and show heterogeneous effects.

E. Alternative control sets and matching:
- Use a matched sample of control states similar to treated states on pre-treatment trends and covariates (temperature patterns, baseline consumption, population growth, industrial share). Estimate CS‑DiD on the matched sample as a robustness check.

F. Placebo tests and permutations:
- Randomly reassign adoption years (preserving cohort sizes) and compute distribution of ATT; show where the observed ATT lies relative to this distribution.
- Placebo outcome tests: test whether EERS predicts unrelated outcomes (e.g., state-level population growth, non-energy commodity consumption) to check for spurious correlations.

G. Present event-study with cohort-contribution heatmap:
- For each event-time, show which cohorts contribute and how much weight. Many long-run event-time estimates reflect only a subset of cohorts — display that explicitly.

H. Welfare calculations: be more conservative
- The welfare arithmetic is useful but sensitive to multiple parameters. Present a sensitivity table showing the benefit-cost ratio across plausible ranges of SCC, marginal emissions factor, program cost per MWh saved, and consumer energy prices. Present central estimate and bounds.

I. Re-run some key analyses excluding particular influential states:
- Early adopters such as California and Massachusetts could be influential. Provide leave‑one‑out checks at the state level or at least for the largest treated states to demonstrate robustness.

7. OVERALL ASSESSMENT

Key strengths:
- Policy-relevant question with direct implications for state policy and energy/climate agendas.
- Uses high-quality, long time-series state-level data (EIA, Census).
- Applies modern staggered-DiD estimators and conducts a broad battery of robustness checks.
- Honest discussion of sensitivity (Honest DiD) and potential limitations is a strong plus.

Critical weaknesses:
- Inference for the preferred estimator is incomplete: small-cluster issues are not fully addressed for CS‑DiD; wild bootstrap / permutation inference is only applied to TWFE.
- Large and unexplained industrial-sector effect calls into question the clean causal interpretation. This requires further empirical treatment (controls for industrial composition/trends, triple difference, or exclusion of affected states) or a clearer statement that estimates capture a policy package rather than EERS alone.
- Long-run event-time estimates are identified by a small number of cohorts; this needs explicit cohort-level presentation and cautious interpretation.
- Treatment intensity (stringency / spending) is not exploited but is likely important. Binary treatment limits policy interpretation.

Specific suggestions for improvement (recap):
- Provide small-cluster-robust inference (wild cluster bootstrap or permutation) for the main CS‑DiD ATT and event-study coefficients.
- Present cohort-specific ATTs and pre-trend diagnostics; show which cohorts drive long-run results.
- Investigate the industrial outcome with additional controls and triple-difference tests; re-evaluate the residential ATT conditional on excluding states with large industrial changes.
- Add dose-response analysis using program spending or target strength where possible.
- Perform permutation/placebo inference and leave‑one‑out checks.
- Expand welfare sensitivity analysis across parameter ranges and make benefit-cost claims more contingent on these ranges.

8. DECISION (REQUIRED)

Given the above, I recommend a major revision. The paper asks an important question and is on the right methodological path, but the inference and identification concerns are substantive and must be addressed before the paper is acceptable for a top general-interest journal.

DECISION: MAJOR REVISION

If you resubmit, please highlight in a cover letter how you addressed each of the critical points above: (i) how you supply small-cluster-robust inference for your preferred CS‑DiD estimates, (ii) how you resolved/clarified the industrial-sector anomaly, (iii) cohort-level diagnostics and sensitivity checks, and (iv) additional robustness (dose-response, permutation tests). If you would like, I can re-review the revised draft and provide more detailed comments on the new analyses.